Stockscreener 앱 받기
285.42
0.71%
2.02
Abbvie Inc 주식(ABBV)의 최신 뉴스
Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment? - Yahoo Finance
AbbVie vs. Merck: Which Pharma Stock Offers Better Value? - Yahoo Finance
AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive? - Yahoo Finance
5 Stock Ideas for Your Short List - TradingView
5 Stock Ideas for Your Short List - Zacks Investment Research
Scotiabank lifts target for AbbVie stock from USD 280.00 to USD 320.00 - ad-hoc-news.de
AI Stocks Lose Steam as Capital Rotates — Eli Lilly, AbbVie Near Record Highs - BigGo Finance
Form 4 AbbVie Inc For: 16 October By Investing.com - Investing.com Nigeria
Breaking Down The Big 3 Investing Strategies - Zacks Investment Research
Abbvie Inc. Announces Appointment of John M. Carethers as Director and Member of Public Policy and Sustainability Committee - www.marketscreener.com
The Dividend Divide: Pure Dividend Strategy ETF Meets Tech-Driven Growth ETF - The Motley Fool
Bristol, AbbVie Seek Intervention in Suit Over Drug Rebate Pilot - Bloomberg Law News
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
AbbVie’s Q3 2026 Earnings: What to Expect - Barchart.com
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research
Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now? - Zacks Investment Research
Lilly, Merck, AbbVie Stocks Surge. Why Healthcare Is Rallying Today. - Barron's
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Inc Stock (ABBV) Moved Up by 3.36% on Oct 14: A Full Analysis - TradingKey
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Yahoo Finance
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
A Look at AbbVie Inc (ABBV) After 2.4% Decline -- GF Value $222. - GuruFocus
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
AbbVie Poised for Q3 Top-Line Beat Driven by Rinvoq, Skyrizi, and Vraylar Therapies, RBC Says - Yahoo Finance
AbbVie (ABBV) Could Be 44% Below Fair Value On Fresh Pipeline Wins - Yahoo Finance
AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts - Zacks Investment Research
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? - The Motley Fool
A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens - The Motley Fool
Cancer Stocks to Consider as Oncology Innovation Accelerates - Zacks Investment Research
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer - Zacks Investment Research
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? - Zacks Investment Research
HSBC Raises AbbVie Price Target to $315 on Immunology Drug Label Expansions - NAI500
AbbVie (ABBV) Pays Out More Than It Earns. How Long Can That Hold? - Yahoo Finance
HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English. - Yahoo Finance
AbbVie's Epkinly Could Be Preferred Frontline DLBCL Agent, UBS Says - marketscreener.com
Abbvie-Genmab Epkinly data signal first-line filing for DLBCL - BioWorld News
AbbVie stock cuts its Q3 EPS guidance to USD 3.730-3.770 - AD HOC NEWS
AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL - Zacks Investment Research
UBS reiterates Abbvie stock rating on positive cancer trial data By Investing.com - Investing.com Canada
Should You Buy AbbVie Stock Before Oct. 30? - Yahoo Finance
AbbVie Rewarded Patient Investors but Punished Those Who Bought on Good News - Yahoo Finance
AbbVie Rewarded Patient Investors but Punished Those Who Bought on Good News - 24/7 Wall St.
Genmab jumps after positive trial of AbbVie-partnered lymphoma drug - Sharecast.com
IYH Beats IXJ on Returns While Global Fund Offers Higher Yield - The Motley Fool
BofA raises target for AbbVie stock from USD 282.00 to USD 289.00 - AD HOC NEWS
Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? - Zacks Investment Research
0.90%
0.76%
자본화:
|
볼륨(24시간):